Form 4: Syros Pharmaceuticals Director Nancy A. Simonian Reports Acquisition of Shares and Stock Options

Director Nancy A. Simonian reports acquiring 4,000 shares of common stock and stock options for 6,000 shares in Syros Pharmaceuticals.

Summary

• On June 5, 2024, Nancy A. Simonian, a director of Syros Pharmaceuticals, acquired 4,000 shares of common stock at $0.00 per share.
• Simonian also acquired stock options for 6,000 shares with an exercise price of $5.30, expiring on June 4, 2034.
• Following these transactions, Simonian directly owns 135,658 shares of common stock and options for 6,000 shares.
• The stock options vest over one year, with 50% vesting after six months and the remainder vesting monthly.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The acquisition of shares and options could be seen as a positive signal, but it's not definitively indicative of strong positive sentiment.

Positives

• A director's acquisition of shares and options may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a company director.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Common Stock, Syros Pharmaceuticals, Director, Simonian, SYRS